Kestra Medical Technologies (NASDAQ:KMTS) Director Sells 3,330 Shares of Company Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) Director Raymond Cohen sold 3,330 shares of the company’s stock in a transaction dated Wednesday, September 30th. The shares were sold at an average price of $29.28, for a total transaction of $97,502.40. Following the completion of the sale, the director directly owned 54,790 shares of the company’s stock, valued at $1,604,251.20. The trade was a 5.73% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kestra Medical Technologies Price Performance

Shares of KMTS traded down $1.18 during mid-day trading on Thursday, hitting $27.11. The company’s stock had a trading volume of 371,350 shares, compared to its average volume of 346,206. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.69 and a quick ratio of 4.69. The firm has a 50-day moving average price of $25.59 and a 200 day moving average price of $22.93. Kestra Medical Technologies, Ltd. has a fifty-two week low of $17.34 and a fifty-two week high of $30.00. The stock has a market capitalization of $1.61 billion, a price-to-earnings ratio of -10.15 and a beta of 0.62.

Kestra Medical Technologies (NASDAQ:KMTS) last released its earnings results on Monday, September 14th. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.61) by ($0.14). The business had revenue of $30.97 million for the quarter. Kestra Medical Technologies had a negative net margin of 140.43% and a negative return on equity of 63.83%. On average, research analysts predict that Kestra Medical Technologies, Ltd. will post -2.45 EPS for the current fiscal year.

Institutional Trading of Kestra Medical Technologies

Several large investors have recently added to or reduced their stakes in KMTS. Brown Advisory Inc. lifted its holdings in shares of Kestra Medical Technologies by 34.1% in the fourth quarter. Brown Advisory Inc. now owns 1,688,356 shares of the company’s stock valued at $44,775,000 after purchasing an additional 428,996 shares in the last quarter. Summit Partners Public Asset Management LLC purchased a new position in shares of Kestra Medical Technologies during the fourth quarter valued at $9,282,000. Next Century Growth Investors LLC raised its position in Kestra Medical Technologies by 154.5% during the fourth quarter. Next Century Growth Investors LLC now owns 465,845 shares of the company’s stock valued at $12,354,000 after buying an additional 282,832 shares during the period. Eventide Asset Management LLC raised its position in Kestra Medical Technologies by 5.4% during the fourth quarter. Eventide Asset Management LLC now owns 1,269,651 shares of the company’s stock valued at $33,671,000 after buying an additional 65,288 shares during the period. Finally, Corient Private Wealth LP lifted its stake in Kestra Medical Technologies by 284.2% in the 2nd quarter. Corient Private Wealth LP now owns 60,614 shares of the company’s stock worth $1,542,000 after acquiring an additional 44,839 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the company. BTIG Research restated a “buy” rating and issued a $32.00 target price on shares of Kestra Medical Technologies in a report on Tuesday, September 15th. Wall Street Zen downgraded Kestra Medical Technologies from a “hold” rating to a “sell” rating in a report on Saturday, September 12th. Royal Bank Of Canada set a $30.00 price target on Kestra Medical Technologies in a research report on Tuesday, September 15th. Wolfe Research set a $30.00 price objective on Kestra Medical Technologies in a report on Wednesday, July 15th. Finally, Piper Sandler reaffirmed an “overweight” rating on shares of Kestra Medical Technologies in a research note on Tuesday, September 15th. Four research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Kestra Medical Technologies presently has a consensus rating of “Hold” and an average target price of $28.38.

Kestra Medical Technologies Company Profile

Kestra Medical Technologies, Inc is a medical device company focused on developing and commercializing technologies for patients at risk of sudden cardiac arrest. The company’s primary product is the ASSURE wearable cardioverter defibrillator, a wearable system designed to continuously monitor a patient’s heart rhythm and deliver an electrical shock when a life-threatening arrhythmia is detected.

The ASSURE system is intended to provide temporary protection for patients who may be at elevated risk of sudden cardiac death but are not yet candidates for, or are awaiting, an implantable cardioverter-defibrillator.